research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
Search
for
Sort by
Research
630-660 / 1000+ results research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata
Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
research Treatment of severe alopecia areata with oral tofacitinib: A case series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research Diagnostic Significance of MIG (Monokine Induced by Gamma Interferon) and IP-10 (Interferon gamma-induced protein 10) Chemokines in Alopecia Areata
Higher levels of MIG and IP-10 may help diagnose and monitor Alopecia Areata.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis
Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
research Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Efficacy of tofacitinib as an induction agent in severe alopecia areata compared to oral betamethasone weekly pulse
Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
research Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders
TYK2 inhibitors show promise for treating cancer and autoimmune disorders.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
research Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
research Letter in Reply: Alopecia areata after SARS-CoV-2 vaccination
A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.
research The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
research ISID1343 - Efficacy of asymmetric siRNA targeting androgen receptor for the treatment of androgenetic alopecia
The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.
research [Acceptability, tolerance and quality of life impact of cyproterone acetate treatment in female hirsutism. Comparison of 2 protocols in combination with oral or transdermal estradiol].
Cyproterone acetate with estradiol improved women's self-confidence and emotional well-being without a difference between oral or transdermal methods, but younger women preferred the oral method.
research Hair Growth in a Patient with Alopecia Areata on Tocilizumab
A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.
research [Long-term treatment of virilized women with cyproterone acetate (author's transl)].
Cyproterone acetate effectively treats virilized women, especially under 35, despite some side effects.
research Irish dermatologists’ experience with JAK inhibitors in alopecia areata
Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
research SARS-CoV-2 vaccination in androgen sensitive phenotypes – A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients
Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research Cyproterone Acetate Quantification in Human Plasma by High-performance Liquid Chromatography Coupled to Atmospheric Pressure Photoionization Tandem Mass Spectrometry
The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.
research Peptichemio: A New Oncolytic Drug in Combination with Vincristine and Prednisolone in the Treatment of Non-Hodgkin Lymphomas
The treatment was effective for advanced non-Hodgkin's lymphomas.